Carenoprazan hydrochloride is under clinical development by Jiangsu Carephar Pharmaceutical and currently in Phase III for Reflux Esophagitis (Gastroesophageal Reflux Disease). According to GlobalData, Phase III drugs for Reflux Esophagitis (Gastroesophageal Reflux Disease) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Carenoprazan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Carenoprazan hydrochloride overview

Carenoprazan hydrochloride is a new-generation candidate acts by targeting potassium ions. It is formulated as tablets for oral route of administration. Carenoprazan hydrochloride is indicated for the treatment of duodenal ulcer and reflux esophagitis.

Carenoprazan hydrochloride is under development for the treatment of peptic ulcers, gastric ulcer, duodenal ulcer and reflux esophagitis. It is administered through oral route as tablets and parenteral route. It is a new-generation candidate acts by targeting potassium ions. The drug candidate is a potassium-competitive acid blocker (P-CAB).

For a complete picture of Carenoprazan hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.